Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.76 |
| ▸ | MME | P08473 | 2/20 | 0.71 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10443978 | 1.00 | LTA4H (0.76) | LTA4HMMEOPRD1 | |
| SCHEMBL1396480 | 1.00 | LTA4H (0.76) | LTA4HMMEOPRD1 | |
| SCHEMBL19707913 | 1.00 | LTA4H (0.76) | LTA4HMMEOPRD1 | |
| SCHEMBL29780321 | 1.00 | LTA4H (0.76) | LTA4HMMEOPRD1 | |
| Hydrochloric Acid SCHEMBL29262753 | 0.99 | LTA4H (0.74) | LTA4HMMEOPRD1 | |
| Hydrochloric Acid SCHEMBL30698084 | 0.99 | LTA4H (0.74) | LTA4HMMEOPRD1 | |
| Hydrochloric Acid SCHEMBL29262752 | 0.99 | LTA4H (0.74) | LTA4HMMEOPRD1 | |
| SCHEMBL17164618 | 0.97 | LTA4H (0.72) | LTA4HMME | |
| SCHEMBL30051506 | 0.97 | LTA4H (0.72) | LTA4HMMEOPRD1 | |
| SCHEMBL17164621 | 0.97 | LTA4H (0.72) | LTA4HMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023083197-A1 | METABOLIC MARKER FOR DIAGNOSING OR MONITORING LUNG CANCER, AND SCREENING METHOD THEREFOR AND USE THEREOF | 武汉迈特维尔医学科技有限公司 | 2023-05-19 | — | — | WO | claimed |
| EP-3805756-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| CN-106537145-B | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | 麦特博隆股份有限公司 | 2020-08-25 | — | — | CN | claimed |
| EP-3129909-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| EP-2363116-A1 | Sustained-release formulations comprising lofexidine for oral delivery | US Worldmeds LLC (US) | 2011-09-07 | — | — | EP | claimed |
| EP-2309993-A1 | SKIN PATCHES AND SUSTAINED-RELEASE FORMULATIONS COMPRISING LOFEXIDINE FOR TRANSDERMAL AND ORAL DELIVERY | US Worldmeds LLC (US) | 2011-04-20 | — | — | EP | claimed |
| EP-2288334-A1 | COMPOSITION AND METHOD FOR TRANSMUCOSAL DELIVERY OF LOFEXIDINE | US Worldmeds LLC (US) | 2011-03-02 | — | — | EP | claimed |
| WO-2009158477-A1 | SKIN PATCHES AND SUSTAINED-RELEASE FORMULATIONS COMPRISING LOFEXIDINE FOR TRANSDERMAL AND ORAL DELIVERY | US WORLDMEDS LLC (US) | 2009-12-30 | — | — | WO | claimed |
| WO-2009120735-A1 | COMPOSITION AND METHOD FOR TRANSMUCOSAL DELIVERY OF LOFEXIDINE | US WORLDMEDS LLC (US) | 2009-10-01 | — | — | WO | claimed |
| US-7569208-B2 | Diagnostic agents for pancreatic exocrine function | TOKYO GAS COMPANY LIMITED (JP) | 2009-08-04 | — | — | US | claimed |
| US-20070189966-A1 | Diagnostic agents for pancreatic exocrine function | TOKYO GAS COMPANY LIMITED | 2007-08-16 | — | — | US | claimed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | claimed |
| CN-119968127-A | Animal food compositions with improved palatability and customizable properties and methods of making the same | 玛氏公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-118948716-A | Application of rice ferment in preparing product with skin care effect | 麦吉丽生物科技有限公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
| EP-0127108-B1 | PROCESS FOR PREPARING POLYPEPTIDES | MERCK & CO. INC. (US) | 1986-12-30 | — | — | EP | disclosed |
| US-4510083-A | POTASSIUM, CESIUM OR RUBIDIUM CARBONATE BUFFER FOR COUPLING OF AMINO ACID N-CARBOXYANHYDRIDE WITH ANOTHER AMINO ACID OR PEPTIDE | MERCK & CO., INC. (US) | 1985-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070189966-A1 | Diagnostic agents for pancreatic exocrine function | AMY2A, IAPP, AMY1A | LTA4H 2053/4885MME 441/4885OPRD1 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.